Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JZP047 · 1 trial · 1 indication
Area under the concentration-time curve from time 0 to 24 (AUC0-24), 0 to last measurable concentration (AUClast), and 0 to infinity (AUC∞) will be assessed.
| Arm | Type | Description |
|---|---|---|
| Part A: JZP047 | EXPERIMENTAL | Healthy participants who are randomized to JZP047. |
| Part A: Placebo | PLACEBO_COMPARATOR | Healthy participants who are randomized to placebo. |
| Part B: JZP047 | EXPERIMENTAL | Healthy participants who will receive JZP047. |
| Name | Type | Description |
|---|---|---|
| JZP047 | DRUG | Single dose |
| Placebo | OTHER | Single dose |
Participants are eligible to be included in the study only if all of the following criteria apply: 1. Healthy participants 18 to 55 years of age, willing and able to comply with study requirements. 2. Male participants are eligible to participate if they agree to the following during the study inte...
JZP047 is an investigational small molecule drug being developed by Jazz Pharmaceuticals plc. It is currently in Phase 1 clinical development, with a single active trial evaluating it in healthy adult participants. No therapeutic indication for JZP047 has been disclosed.
JZP047 is being developed by Jazz Pharmaceuticals plc, which trades on the Nasdaq under the ticker JAZZ. The company is the sponsor of the Phase 1 study of JZP047 in healthy participants.
JZP047 is in Phase 1 clinical development. It has one active, recruiting trial and no completed trials. JZP047 is investigational and has not been approved by the FDA for any indication.
JZP047 is being studied in one Phase 1 trial, NCT07377539, titled A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants. The trial is recruiting in the United States and is expected to enroll 86 healthy volunteers aged 18 years and older.
The JZP047 Phase 1 trial NCT07377539 is a randomized, double-blind, placebo-controlled study in healthy participants. It is designed to assess safety, tolerability, pharmacokinetics, and food effect, and it plans to enroll 86 participants across both sexes in the United States.